Supplementary Data from U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Autor: | Sai-Hong Ignatius Ou, Pasi A. Jänne, Takashi Seto, Yanfei Gao, Qinying Zhao, Frank Fan, Meijing Li, Chenhui Deng, Kenji Nakamaru, Takeshi Isoyama, Masaya Tachibana, Hiroyuki Hanzawa, Naoki Nakao, Giorgio Senaldi, Alexa B. Schrock, Russell Madison, Heather A. Wakelee, Thomas Yang Sun, Viola W. Zhu, Yuki Shimizu, Ryohei Katayama, Alice T. Shaw, Erkut Borazanci, Kyriakos P. Papadopoulos |
---|---|
Rok vydání: | 2023 |
Popis: | Supplemental tables and figures |
Databáze: | OpenAIRE |
Externí odkaz: |